Summary Fluctuation analysis experiments were performed to assess whether selection or induction determines expression of Pglycoprotein and resistance in the murine Ehrlich ascites tumour cell line (EHR2) after exposure to daunorubicin. Thirteen expanded populations of EHR2 cells were exposed to daunorubicin 7.5 x 10`8 M or 10-8 M for 2 weeks. Surviving clones were scored and propagated. Only clones exposed to daunorubicin 7.5 x 10-9 M could be expanded for investigation. Drug resistance was assessed by the tetrazolium dye (MTT) cytotoxicity assay. Westem blot was used for determination of P-glycoprotein. Compared with EHR2, the variant cells were 2.5-to 5.2-fold resistant to daunorubicin (mean 3.6-fold). P-glycoprotein was significantty increased in 11 of 25 clones (44%). Analysis of variance supported the hypothesis that spontaneous mutations conferred drug resistance in EHR2 cells exposed to daunorubicin 7.5 x 10-9 M. At this level (5 log cell killing) of drug exposure, the mutation rate was estimated at 4.1 x 10-6 per cell generation. In contrast, induction seemed to determine resistance in EHR2 cells in vitro exposed to daunorubicin 10-8 M. The revertant EHR2/0.8/R was treated in vivo with daunorubicin for 24 h. After treatment, P-glycoprotein increased in EHR2/0.8/R (sevenfold) and the cell line developed resistance to daunorubicin (1 2-fold), suggesting that in EHR2/0.8/R the mdrl gene was activated by induction. In conclusion, our study demonstrates that P-glycoprotein expression and daunorubicin resistance are primarily acquired by selection of spontaneously arising mutants. However, under certain conditions the mdrl gene may be activated by induction.
Several reports indicate that transcription of the mdrl gene can be induced in cell lines. Thus. a varietv of environmental stresses and circumstances that affect cellular differentiation have been shown to induce m4drl gene expression (Chin et al. 1990a : Mickley et al. 1996 . The anthracycline doxorubicin has been shown to induce expression of P-gp after only 24 h of contact with sensitive cells (Volm et al. 1991 : Chevillard et al. 1992 . The mdrl promoter has been shown to respond directly to treatment with anthracyclines or xinca alkaloids (Kohno et al. 1989 ). On the other hand. fluctuation analysis expenrments have indicated that activation of the mdrl gene in human sarcoma cells occurs as a result of a stochastic process consistent with mutational events .
The purpose of the present study was: (1) to use Luria-Delbruck fluctuation analysis to investigate whether daunorubicin (DNR) induced P-gp in sensitive Ehrlich ascites tumour cells (EHR2) by mutation or induction: (2) to investigate whether P-gp could be induced in EHR2 by 24 h treatment in vivo with DNR: (3) to investigate the expression of P-gp after 24-h treatment m X ivo with DNR in cells that are retreated after reversal of resistance.
MATERIALS AND METHODS

Chemicals
Daunorubicin as hydrochloride w-as purchased from Farmitalia Carlo Erba. Milan. Italy. All other chemicals were of analytical grade.
Tumour cells
The murine Ehrlich ascites tumour cell line (EHR2) xas used in the experiments. The cell line was maintained as ascites tumours in mice by weekly transplantation of 1.5 x 10-cells per mouse and established as an in Xitro culture.
The mice used xxere first-generation hybrids of female NRMI and male inbred DBA/2 mice 1 8-22 g). The mice xxere bred at the department. The study complied wxith the Danish and EU regulations for animal wxelfare. The tissue culture medium used was RPMI-1640 supplemented with 10%7 fetal calf serum (FCS) . L-glutamine (0. 29 g 1-1). penicillin (200 000 IU 1-1) and streptomycin (50 mg 1-1). The plating efficiency of EHR2 was 65%7c. Exponentially growxing cells were used for all experiments. The rexertant EHR2/0.8/R was dexeloped from the resistant EHR2/0.8 subline. This subline (EHR2/0.8) was maintained in xivo bv intraperitoneal treatment with DNR 0.8 mc kg-' x 4 weekly corresponding to 50%7 of the LD dose (Nielsen et al. 1994) . Compared with EHR2. EHR2/0.8 was highly resistant to DNR (35-fold) and had increased expression of P-gp (21 -fold). To develope EHR2/0.8/R. the treatment was discontinued after 54 passages (12 months) and the cell line was passaced for a further 60 passages (14 months) without treatment. Compared with EHR2. EHRIJO.8/R was 2.4-fold resistant to DNR. A semiquantification of P-gp with Western blot showed that P-gp expression in EHR2/0.8/R xxas similar to the expression in EHR' (12 ± 3 and 12 ± 4 arbitrarv units respectixelv: Nielsen et al. 1994 ).
In vixvo induction of P-op in EHR' and EHR2/0.8/R cells respectively was studied by treatment of the mice wvith DNR 6 mg kg'. on the 6th day of transplantation. Investigation of these cells was performed after 24 h of contact w ith DNR.
The resistant subline EHR2IDNR+ was used for calibration of the Western blot assay and as a positixve control for immunocytochemical analysis (Nielsen et al. 1994 ).
Determination of drug resistance
Growth inhibition was evaluated by the tetrazolium dye colorimetric assay (MTT; 3-4-5-dimethyl-2-thiazolyl-2.5-diphenvl-2H-tetrazolium bromide: Tada et al. 1986 Determination of cellular proliferation Cellular proliferation was measured as described by Chen et al (1994) . EHR2 cells and variant cells were seeded in 96 plates and incubated for 72 h at 370C wxith 5% carbon dioxide. Cell growth was estimated by the MYT colometric method (Tada et al. 1986 (1951) . Caulated according to Luria-DelbrOck (1943) as mnodified by Lea and Coulson (1949) . cNot applicable, as the methodology requires at least one population with no surviving colonies. These selection conditions were chosen based on preliminary expenments.
Surx-iving colonies were allowed to grow for 14 daxys and were then individually harvested and propagated in drug-free medium for further studies. In order to investigate the probabilitx of preexisting resistant clones in the original seeded population. populations of 2000 EHR2 cells were plated in separate 24-well plates and treated directly with DNR (DNR 7.5 10`N and 10-sw: 26 plates per concentration) without expansion of the populations before drug exposure. In this experiment. no survixinc colonies were observed (data not shown).
Analysis of variance and mutation rates The mutation rates were calculated according to the method of Catcheside ( 1951 ) (1998) 78(9), [1175] [1176] [1177] [1178] [1179] [1180] Number of experiments given in parenthesis. two or three mice were used for every experiment.
Following electrophoresis. proteins were transferred to nitrocellulose paper. The paper was blocked. incubated overnirht with C219 (Centocor Diagnostics. Philadelphia. PA. USA). and for 2 h with peroxidase-conjugated F(ab') fragments of affinity-purified sheep anti-mouse IgG (Medac. Hamburg. Germany).
The expression of P-gp was determined by reflectance photometrv. The relati've content of P-gp was calculated using a standard curve composed of membrane preparations with defined concentrations of P-gp (Nielsen et al. 1994 
RESULTS
Fluctuation analysis
The data presented in Table 1 show the number of surviving colonies in the plates (two plates per population) from each group studied by fluctuation analysis. In the group exposed to DNR 7.5 x 10-9 xi. the mean number of colonies sur iving per plate was 52. with a variance of 712. In the group exposed to DNR lO' M. the mean number of colonies surviving per plate was only 1.5.
with a variance equal to the mean.
Determination of mutation rates Fluctuation analysis was also used to determine rates for DNR resistance in the EHR2 clones. According to the method of Catcheside ( 195 1 ). the mutation rate was estimated to be 4. 1 x I0o at DNR 7.5 x 1X9 M. whereas it decreased to 1.2 x l0--at a drug concentration of l0-mi.
Drug resistance, expression of P-gp A total of 25 clones were propagated from the group that was treated with DNR 7.5 x 10-9 M. At least one clone from each population was represented. All clones were stable. The resistance is shown in Table 2 . Compared with EHR2 the degree of resistance varied from 2.5-to 5.2-fold (mean 3.6-fold). None of the resistant clones manifested any significant difference in generation time. Among the propagated clones 11 (44%) showed significantly increased expression of P-gp as compared with EHR2 (Table 2) .
Nineteen clones were isolated in the group that was treated with DNR 108 M; however, none of these clones could be propagated for fturther studies.
Treabrment in vivo Sensitive Ehrlich ascites tumour cells
Sensitive EHR2 cells were treated in vivo with DNR; 6 mg kg-' for 24 h. The experiment was repeated five times using 2-3 mice every time. The expression of P-gp in teated cells was mean 15 ±8 (s.d.) arbitrary units. The expression of P-gp in EHR2 has previously been determined to be 12±4 units (Nielsen et al, 1994) . In the present study, treatment with DNR for a short period of time in vivo did not induce P-gp in sensitive cells.
Revertant Ehrlich ascites tumour cells EHR2/).8/R was treated in vivo with DNR 6 mg kg-' for 24 h. The experiment was repeated six times using two or three mice every time. The expressions of P-gp are given in Table 3 . In three instances the measurements were continued to day 15, in one instance P-gp expression was followed to day 240. The cell lines were passaged every seventh day in these periods. The expression of P-gp increased significantly in the treated tumours, showing the highest expression from days 15 to 45. Immunocytochemistry analysis was performed 1 day after treatment with DNR. This analysis showed a uniform weak immunoreactivity of cytoplasma and cell membrane of the EHR2/0.8/R cells, not different from EHR2 cells. None of the EHR2/0.8/R cells showed significantly increased expression of P-gp (data not shown).
The cytotoxicity of DNR was investigated immediately after tratnent (day 1), the DNR-treated EHR2/0.8/R cells were 11.9-fold resistant compared with EHR2 and 4.9-fold resistant compared with EHR210.8/R.
DISCUSSION
Knowledge regarding the genetic and biochemical nature of drug resistance has been derived largely from cellular models developed by multistep, long-term drug exposure. Little is known about the initial genetic changes and relative frequencies of activation of various drug resistance mechanisms in tumour cell populations. The theory of genetic instability of tumours suggested by Goldie and Coldman (1979) proposes that drug-resistant cells emerge from the clonal expansion of spontaneously mutated cells, rather than from changes in cellular function induced by the drugs. This theory is based on the classic fluctuation analysis experiments performed by Luria and Delbrick (1943) Moreover, the clones that are scored must arise during the expansion of the parallel cultures (Kendal and Frost, 1988) . If a resistant cell was present in the initial seeding of 2000 EHR2 cells, at least 2048 progeny would have been present after 11 generations of growth. The highest number of surviving colonies among our expanded populations was 87, indicating that the event responsible for the cell survival occurred after a minimum of five generations of population expansion. Furthermore, the pre-existence of resistant variants in the initial cell population was unlikely, as none of the cell clones survived when the parental EHR2 cells were treated with DNR without prior expansion.
Tlhe literature is generally unclear on the precise events regulating the appearance of P-gp-mediated resistance. Both induction and selection have been described, with no compelling evidence prented to support definitively one or other mechanism as overriding in all cellularhumour models. Prior studies have been performed in many different cells lines, using different drugs, exposures and analytical approaches. It is possible that the various conclusions apparent in the literature could reflect these different experimental conditions. On the other hand, Chen et al (1994) used fluctuation analysis to investigate the resistance mechanisms in human sarcoma (MES-SA) cells exposed to the anthracycline doxorubicin. In accordance with our result, these authors demonstrated that spontaneous mutations conferred resistance to doxorubicin. These authors also used the Luria and Delbriick fluctuation analysis to investigate resistance mechanisms in MES-SA cells exposed to paclitaxel (Dumontet et al, 1996) , etoposide ) and a combination of cyclosporin PSC 833 and doxorubicin (Beketic-Oreskovic, 1995) . In all instances except one, analysis of variance supported the hypothesis of spontaneous mutations conferring resistance. In MES-SA cells exposed to a very high dose of etoposide (5 piM), analysis of variance showed the variance equal to the mean . This latter finding was compatible with our finding in EHR2 cells exposed to DNR 10 M, suggesting that at highly stringent conditions of selection (6 log cell killing) the resistance could be a result of adaption.
In the present study, the increase in P-gp was very modest; further, P-gp increased in only 44% of the surviving clones. In contrast, Chen et al (1994) in MES-SA cells exposed to doxorubicin observed increased mRNA mdrl in all clones tested . The expression of P-gp in these cells was, however, modest, in accordance with our results (3-9% compared with control, MDR cells). In addition, Dumontet et al (1996) demonstrated increased rndrl mRNA in only 4 of 9 clones of MES-SA clones exposed to paxlitaxel. Besides overexpression of the mdrl gene, which is the predominant mechanism of resistance to DNR. cells can manifest resistance to this agent by decreased expression and/or altered activity of topoisomerase II. Other reported mechanisms of resistance include alteration in cellular glutathione level. expression of multidrug resistance-associated protein (MRP) or expression of lung resistance protein (LRP) (Nielsen et al. 1996) .
Compared with EHR2. the degree of resistance of the surviving clones was modest (2.5 to 5.2-fold). This finding is in agreement with the finding of Jaffrezou et al (1994) . who used etoposide as selecting arent. In the previously mentioned studies the degrees of resistance were. however. found to be significantly higher . Betetic-Oreskovic et al. 1995 . Dumontet et al. 1996 .
The rate of mutation conferring resistance to DNR w-as 4.1 x 10-per cell reneration. The statistical errors associated with variation rate measurements are considerable (Kendal and Frost. 1988) . On the other hand. the mutation rate was in the range of spontaneous point mutations described for mammalian cells (10--10-per cell generation) (Borst. 1991) and comparable with that previously described in human sarcoma (MES-SA) cells . Dumontet et al. 1996 : but lower than that described for some gene amplifications. ranging from 1 to 7 x 10-' per cell generation (Crawford et al. 1983 . Tlsty et al. 1989 ).
In the present study. P-p could be induced in EHR2/0.8/R by 24 h treatment with DNR in vivo. but not in sensitive EHR2 cells.
The inducibility of the mdrl gene and P-gp by treatment with cytostatics has been investigated bv several authors (Kohno et al. 1989 : Chin et al. 1990b : Chaudharv and Roninson. 1993 : Fardel et al. 1997 . In contrast to our finding. P-gp could be induced in sensitive cells. Kohno et al (1989) found that the mdrl promoter w-as activated by vincristine. anthracyclines and colchicine. Chin et al (1990b) Chevillard et al (1992) reported increased P-gp expression to be induced in sensitive human lung adenocarcinoma cells (A549) after 24 h treatment with doxorubicin. The emerguence of P-gp was follow ed by approximately three-fold resistance to doxorubicin. P-gp has been found to be dose dependently induced in a human pleural mesothelioma xenograft (PXF 1118) (Licht et al. 1991) . In this cell line. P-gp was induced in absence of proliferation. thus favouring the proposal that increased expression of P-gp is associated with phenotypic cell change rather than resulting from selection of a pre-existing drugy-resistant subpopulation.
In general the degree of resistance induced in sensitive cells after transient treatment with cytostatic was low (2 to 3-fold) (Licht et al. 1991 . Volm et al. 1991 : Chevillard et al. 1992 ). In contrast. the EHR2/0.8/R cell line developed sig'nificant resistance to DNR ( 11.9-fold). Previously. the expression of P-gp in revertant cell lines has only been investigated by Gekeler et al (1988) . In an actinomycin A-selected human leukaemia cell line maintained 1 month without selection pressure. mdrl gene transcription was inducible after 72 h of retreatment. In this cell line the degree of resistance was. how7ever. not investigated.
In the present study. immunocvtochemistrv showed a uniform Aweak immunoreactivitv of the treated EHR20.8/R cells. not significantly different from EHR2. The expression of P-gp was probably below the detection himit of the immunocvtochemistrv assay. Thus. this finding suggested that P-gp was induced in a high fraction of the EHR2/0.8/R cells. In spite of cessation of treatment P-gp increased further after transplantation of EHR2/0.8/R. reaching, the highest level from days 15-45. This high expression of P-gp was comparable with the expression of P-gp in EHR2 cells. which had been exposed to multiple doses of DNR (Nielsen et al. 1994) . This finding could be in accordance with either a direct activation of the mdrl promoter as described by Kohno et al (1989) or an indirect activation of the promoter by interaction with a regulatory protein (Gant et al. 1992) . sugaesting that the activation of the mdrl gene occurred by induction.
In conclusion. our study demonstrates that P-gp expression and DNR resistance are primarilv acquired by selection of spontaneously arising mutants. However. under certain conditions the mdrl gene could be activated by induction. ABBREVIATIONS DNR. daunorubicin: MDR. multidrugy resistance: P-gp. P-glycoprotein
